Alpha Cognition Inc. (ACOGF)
USD 5.73
(N/A%)
USD 5.73
(N/A%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -183.78 Thousand USD | 78.93% |
| 2022 | -872.23 Thousand USD | 91.47% |
| 2021 | -10.22 Million USD | -277.16% |
| 2020 | -2.71 Million USD | 41.6% |
| 2019 | -4.64 Million USD | -1748.66% |
| 2018 | -251.12 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 192.6 Thousand USD | 115.98% |
| 2024 Q1 | -1.2 Million USD | -555.94% |
| 2023 Q4 | -183.78 Thousand USD | -140.86% |
| 2023 FY | -183.78 Thousand USD | 78.93% |
| 2023 Q3 | 449.83 Thousand USD | 680.51% |
| 2023 Q2 | -77.48 Thousand USD | 97.14% |
| 2023 Q1 | -2.7 Million USD | -210.66% |
| 2022 Q4 | -872.23 Thousand USD | 65.72% |
| 2022 FY | -872.23 Thousand USD | 91.47% |
| 2022 Q2 | -4.83 Million USD | 39.38% |
| 2022 Q1 | -7.97 Million USD | 22.01% |
| 2022 Q3 | -2.54 Million USD | 47.37% |
| 2021 Q3 | -3.68 Million USD | 13.05% |
| 2021 Q2 | -4.23 Million USD | 32.2% |
| 2021 Q1 | -6.25 Million USD | -1353.57% |
| 2021 Q4 | -10.22 Million USD | -177.42% |
| 2021 FY | -10.22 Million USD | -277.16% |
| 2020 Q3 | -6.25 Million USD | 0.0% |
| 2020 FY | -2.71 Million USD | 41.6% |
| 2020 Q4 | 498.78 Thousand CAD | 107.98% |
| 2019 Q4 | -4.64 Million USD | -184.45% |
| 2019 Q3 | 5.49 Million USD | 0.0% |
| 2019 FY | 191.51 Thousand USD | -1748.66% |
| 2018 FY | -251.12 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -13929.618% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 103.254% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.429% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 26.373% |
| Rebus Holdings, Inc. | 305 Thousand USD | 160.258% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 97.085% |
| Qrons Inc. | 351.42 Thousand USD | 152.298% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 129.531% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.423% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -800.568% |
| Skye Bioscience, Inc. | -5.72 Million USD | 96.788% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 101.166% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 104.463% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 145.736% |
| SQZ Biotechnologies Company | -36.23 Million USD | 99.493% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 108.197% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 119.822% |
| Mesoblast Limited | 55.85 Million USD | 100.329% |
| Marizyme, Inc. | 18.56 Million USD | 100.99% |
| Genus plc | 190.6 Million USD | 100.096% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 108.22% |
| Pharming Group N.V. | 109.8 Million USD | 100.167% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 121.365% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 115.14% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 127.028% |
| ContraFect Corporation | -6.02 Million USD | 96.95% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 236.504% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 115.906% |
| IMV Inc. | 7.67 Million USD | 102.396% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 103.34% |
| MultiCell Technologies, Inc. | 90.04 USD | 204218.17% |
| ONE Bio Corp. | 9.04 Million USD | 102.033% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 74.96% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 101.42% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 113.435% |
| Q BioMed Inc. | 4.06 Million USD | 104.527% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 100.602% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 118.238% |
| Biomind Labs Inc. | 711.4 Thousand USD | 125.835% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.304% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 109.192% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 101.435% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 151.093% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 231.461% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 1025.092% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 108.346% |
| GB Sciences, Inc. | 1.74 Million USD | 110.518% |
| HST Global, Inc. | 96.79 Thousand USD | 289.877% |
| CSL Limited | 10.52 Billion USD | 100.002% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 189.124% |
| Halberd Corporation | 144.72 Thousand USD | 226.995% |
| Enzolytics Inc. | 981.65 Thousand USD | 118.722% |
| Agentix Corp. | 37.63 Thousand USD | 588.395% |
| Resverlogix Corp. | 6.45 Million USD | 102.849% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 72.695% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.991% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 99.609% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 102.599% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 106.785% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 97.921% |
| AVAX Technologies, Inc. | -5.9 Million USD | 96.887% |
| Zenith Capital Corp. | 10.06 Thousand USD | 1926.192% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.983% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 191.696% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 107.703% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 211.719% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -903.319% |
| Kadimastem Ltd | -253.1 Thousand USD | 27.386% |
| Helix BioMedix, Inc. | -2.57 Million USD | 92.849% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 100.906% |
| BioStem Technologies, Inc. | 4.47 Million USD | 104.11% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 191.321% |
| LadRx Corporation | -2.03 Million USD | 90.975% |
| Cell Source, Inc. | 9.23 Million USD | 101.991% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 128.935% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 128.935% |
| NovAccess Global Inc. | 2.17 Million USD | 108.437% |
| Affymax, Inc. | -5.59 Million USD | 96.716% |
| Itoco Inc. | 228.3 Thousand USD | 180.501% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 235.149% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 103.708% |
| Mobile Lads Corp. | 484.23 Thousand USD | 137.955% |
| CytoDyn Inc. | 20.26 Million USD | 100.907% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -28306.182% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -1882.966% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 102.385% |
| SYBLEU INC | 473.71 Thousand USD | 138.797% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 104.124% |
| International Stem Cell Corporation | 2.59 Million USD | 107.096% |
| Bioxytran, Inc. | 1.89 Million USD | 109.679% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 394.471% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 108.427% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 105.352% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 102.149% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 123.788% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 85.297% |
| Neutra Corp. | 52.18 Thousand USD | 452.172% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 92.616% |
| PureTech Health plc | -167.19 Million USD | 99.89% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 24.956% |
| IXICO plc | -4.44 Million USD | 95.865% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 101.39% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.335% |
| CSL Limited | 10.52 Billion USD | 100.002% |
| Cellectis S.A. | -43.81 Million USD | 99.581% |